Results 11 to 20 of about 3,462 (164)
Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies
Frontiers in Immunology, 2019 Heavy chain-only antibodies (HCAbs) do not associate with light chains and their VH regions are functional as single domains, forming the smallest active antibody fragment.
Ignacio Anegon +2 more
exaly +3 more sources
Potential of alarmin-targeted bispecific and combination therapies in airway disease [PDF]
Frontiers in AllergyThymic stromal lymphopoietin (TSLP), IL-33, and IL-25 are epithelial-derived proinflammatory alarmin cytokines that drive inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease (COPD).
H. Kiyomi Komori, Hector Ortega
doaj +2 more sources
Immune escape mechanism of B-cell malignancies on Anti-CD19 Chimeric Antigen Receptor T-cell treatment and solution [PDF]
E3S Web of Conferences, 2021 Relapse or refractory B-cell malignancies have been reported in multiple clinical trials after treatment of Anti-CD19 Chimeric Antigen Receptor (CAR) T-cells.
Qian Jin
doaj +1 more source
Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies
mAbs, 2023 Upon reformatting of an antibody to single-chain variable fragment format, a region in the former variable/constant domain interface of the heavy chain becomes accessible for preexisting (PE) anti-drug antibody (ADA) binding.
Maria U. Johansson +12 more
doaj +1 more source
mAbs, 2023 A challenge when developing therapeutic antibodies is the identification of candidates with favorable pharmacokinetics (PK) early in development. A key determinant of immunoglobulin (IgG) serum half‑life in vivo is the efficiency of pH-dependent binding ...
Thomas Müller +6 more
doaj +1 more source
mAbs, 2022 Controlled Fab arm exchange (cFAE) has proven to be a generic and versatile technology for the efficient generation of IgG-like bispecific antibodies (DuoBodies or DBs), with several in clinical development and one product, amivantamab, approved by the ...
Desislava Yanakieva +9 more
doaj +1 more source
Multispecific resistance of sheep trichostrongylids in Austria
Parasite, 2021 Anthelmintic overuse and failure to implement methods preventing the development and spread of anthelmintic resistance (AR) have led to an alarming increase of resistant ovine trichostrongylids worldwide.
Untersweg Florian +9 more
doaj +1 more source
Next generation Fc scaffold for multispecific antibodies
iScience, 2021 Summary: Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for ...
Bram Estes +11 more
doaj +1 more source
AlbuCORE: an albumin-based molecular scaffold for multivalent biologics design
mAbs, 2020 As biologics have become a mainstay in the development of novel therapies, protein engineering tools to expand on their structural advantages, namely specificity, affinity, and valency are of interest.
Mario Sanches +13 more
doaj +1 more source
Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics
mAbs, 2022 Immunoglobulin G (IgG) has served as a traditional framework for antibody-based biology, and engineering approaches for creating multispecific therapeutics have greatly expanded its applicability.
Florian Heinkel +11 more
doaj +1 more source